All In MedTech

FDA Clearance Tracker · P240021-S001

Atellica IM Total PSA II (tPSAII)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P240021-S001
Device name
Atellica IM Total PSA II (tPSAII)
Applicant location
Tarrytown, NY
Received
Feb 27, 2026
Decided
Aug 26, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P240021

Device type

Device class
Class III

Every decision under product code MTF

FDA's approval statement

As written in FDA's record.

Approval for the Atellica IM total PSA II (tPSAII):The Atellica IM total PSA II (tPSAII) assay is for in vitro diagnostic use in the quantitative measurement of total prostate-specific antigen (PSA) in human serum and plasma (EDTA and lithium-heparin) using the Atellica CI Analyzer. This assay is indicated as an aid in the detection of prostate cancer in conjunction with a digital rectal exam (DRE) in men aged 50 years and older. A prostate biopsy is required for the diagnosis of prostate cancer.

Source documents

Other decisions for Siemens Healthcare Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.